cerrar
Tagged with R&D

Alzheimer’s Disease R&D Expenditure Snapshot 2019
Alzheimer's drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom, "Except for…

Sweden Pharma R&D Snapshot
Over EUR 1 billion was spent in Sweden on pharmaceutical R&D in 2015, a similar level to spending seen in Italy and Denmark. Made with…

Taiwan Innovation Snapshot
As part of its 'Asia Silicon Valley Development Plan', Taiwan has designated a special focus to each of its regions. The Taiwanese government is…

Pascal Girin – CEO, BALT, France
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D…

The Technology Driving Rare Disease Pipelines
Rhenu Buller, an expert on disruptive technologies at business consultancy Frost & Sullivan's Asia Pacific office, outlines the technological…

Jin Hyoung Kang – President, Cancer Study Group, South…
Dr Jin Hyoung Kang, president of the Cancer Study Group comments on the scope for oncology drug development in Korea, and the issues resulting from…

Jae Cheon Yeo – Executive Director, Korea Drug Research…
Established in 1986, the KDRA is Korea's leading new drug research and development special corporation, established under the Ministry of Science and…

Jeewoong Son – President, LG Life Sciences, South Korea
LG Life Sciences is one the early pioneers of innovative drug development in Korea with a diversified portfolio of chemical drugs, vaccines,…

Daewoong Pharmaceutical: Record Sales and 100 Billion Won…
South Korean heavyweight Daewoong Pharmaceutical saw record sales in 2018, but did see a decrease in its EBITDA figures. To ensure its future…

Top 10 Clinical CROs in Korea
Ten of the top contract research organizations (CROs) currently operating in South Korea, as selected by KoNECT, the Korea National Enterprise for…

“Why We Need Public-Private Partnerships in Drug…
Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI) in Europe, outlines the value of public-private partnerships in drug…

Megatrends from the 2019 Deloitte Life Sciences Outlook
Deloitte's Global Life Sciences & Health Care industry leader, Greg Reh gives us an exclusive insight into their forecast for 2019's industry…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here